Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Andrew Hill
No abstract text is available yet for this article.
April 12, 2024: Clinical Infectious Diseases
#22
JOURNAL ARTICLE
José Damas, Aline Munting, Jacques Fellay, David Haerry, Catia Marzolini, Philip E Tarr, Ana Steffen, Dominique L Braun, Marcel Stoeckle, Enos Bernasconi, Olivier Nawej Tshikung, Christoph A Fux, Katharine E A Darling, Charles Béguelin, Gilles Wandeler, Matthias Cavassini, Bernard Surial
BACKGROUND: Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). While weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study. METHODS: We included participants who received at least six months of TAF-containing ART between January 2016 and March 2023...
April 12, 2024: Clinical Infectious Diseases
#23
JOURNAL ARTICLE
Brittany A Petros, Carly E Milliren, Pardis C Sabeti, Al Ozonoff
BACKGROUND: Respiratory syncytial virus (RSV) circulation dropped markedly early in the COVID-19 pandemic, followed by a resurgence with heightened case counts. The "immunity debt" hypothesis proposes that the RSV-naїve pediatric population increased during the period of low transmission. However, the evidence supporting this hypothesis is limited, and the role of changing testing practices in the perceived surge has not been comprehensively evaluated. METHODS: We conducted a multicenter, retrospective analysis of 342 530 RSV encounters and 980 546 RSV diagnostic tests occurring at 32 US pediatric hospitals in 2013-2023...
April 11, 2024: Clinical Infectious Diseases
#24
JOURNAL ARTICLE
Amy Sherman, Jessica Tuan, Valeria D Cantos, Oladunni Adeyiga, Scott Mahoney, Ana M Ortega-Villa, Amy Tillman, Jennifer Whitaker, Amanda S Woodward Davis, Brett Leav, Ian Hirsch, Jerald Sadoff, Lisa M Dunkle, Peter B Gilbert, Holly E Janes, James G Kublin, Paul A Goepfert, Karen Kotloff, Nadine Rouphael, Ann R Falsey, Hana M El Sahly, Magdalena E Sobieszczyk, Yunda Huang, Kathleen M Neuzil, Lawrence Corey, Beatriz Grinsztejn, Glenda Gray, Martha Nason, Lindsey R Baden, Cynthia L Gay
BACKGROUND: Although the SARS-CoV-2 vaccines are highly efficacious at preventing severe disease in the general population, current data are lacking regarding vaccine efficacy (VE) for individuals with mild immunocompromising conditions. METHODS: A post-hoc, cross-protocol analysis of participant-level data from the blinded phase of four randomized, placebo-controlled, COVID-19 vaccine phase 3 trials (Moderna, AstraZeneca, Janssen, and Novavax) was performed. We defined a "tempered immune system" (TIS) variable via a consensus panel based on medical history and medications to determine VE against symptomatic and severe COVID-19 cases in TIS participants versus non-TIS (NTIS) individuals starting at 14 days after completion of the primary series through the blinded phase for each of the four trials...
April 10, 2024: Clinical Infectious Diseases
#25
JOURNAL ARTICLE
Andreea Dobrescu, Alexandru Marian Constantin, Larisa Pinte, Andrea Chapman, Piotr Ratajczak, Irma Klerings, Robert Emprechtinger, Benedetta Allegranzi, Walter Zingg, M Lindsay Grayson, Joao Toledo, Gerald Gartlehner, Barbara Nussbaumer-Streit
BACKGROUND: Peripheral intravenous catheters (PIVCs) contribute substantially to the global burden of infections. This systematic review assessed 24 infection prevention and control (IPC) interventions to prevent PIVC-associated infections and other complications. METHODS: We searched Ovid MEDLINE, Embase, Cochrane Library, WHO Global Index Medicus, CINAHL and reference lists for controlled studies, from January 1, 1980-March 16, 2023. We dually selected studies, assessed risk of bias, extracted data, and rated the certainty of evidence (COE)...
April 9, 2024: Clinical Infectious Diseases
#26
JOURNAL ARTICLE
Chishala Chabala, Eric Wobudeya, Marieke M van der Zalm, Monica Kapasa, Priyanka Raichur, Robert Mboizi, Megan Palmer, Aarti Kinikar, Syed Hissar, Veronica Mulenga, Vidya Mave, Philippa Musoke, Anneke C Hesseling, Helen McIlleron, Diana Gibb, Angela Crook, Anna Turkova
BACKGROUND: Children living with HIV(CLWH) are at high risk of tuberculosis(TB) and face poor outcomes, despite antiretroviral treatment(ART). We evaluated outcomes in CLWH and HIV-uninfected children treated for non-severe TB in the SHINE trial. METHODS: SHINE was a randomized trial that enrolled children aged <16 years with smear-negative, non-severe TB who were randomized to receive 4 vs 6 months of TB treatment and followed for 72 weeks. We assessed TB relapse/recurrence, mortality, hospitalizations, grade ≥3 adverse events by HIV status, and HIV virological suppression in CLWH...
April 9, 2024: Clinical Infectious Diseases
#27
JOURNAL ARTICLE
M M C Hendriks, K S A Schweren, A Kleij, M A H Berrevoets, E de Jong, P van Wijngaarden, H S M Ammerlaan, A N Vos, S van Assen, K Slieker, E H Gisolf, M G Netea, J Ten Oever, I J E Kouijzer
BACKGROUND: Risk stratification to categorize patients with Staphylococcus aureus bacteremia (SAB) as low- or high-risk for metastatic infection may direct diagnostic evaluation and enable personalized management. We investigated the frequency of metastatic infections in low-risk SAB patients, their clinical relevance, and whether omission of routine imaging is associated with worse outcomes. METHODS: We performed a retrospective cohort study in seven Dutch hospitals among adult patients with low-risk SAB, defined as hospital-acquired infection without treatment delay, absence of prosthetic material, short duration of bacteremia, and rapid defervescence...
April 5, 2024: Clinical Infectious Diseases
#28
JOURNAL ARTICLE
John M Cafardi, Hong T Lin, Lana Lange, Lacey Kelley, Kelly Lemon, Elizabeth A Odegard, Heidi L Meeds, Jason T Blackard, Judith Feinberg
We evaluated vertical transmission and linkage to care in women with HCV and history of injection drug use employing co-localized testing and treatment. Transmission occurred in 1 of 23 infants, with mother-infant genetic distance of 1.26%. Rates for infant testing, maternal linkage and cure were 77%, 52%, and 100%, respectively.
April 5, 2024: Clinical Infectious Diseases
#29
JOURNAL ARTICLE
Davide Moschese, Angelo Roberto Raccagni, Andrea Giacomelli, Antonio Piralla, Roberto Rossotti, Alessandro Raimondi, Daniele Tesoro, Luigi Vezzosi, Maurizio Gulletta, Nicola Clementi, Serena Venturelli, Susanna Benardon, Davide Ricaboni, Dario Bernacchia, Alessandro Mancon, Francesca Rovida, Federica Attanasi, Danilo Cereda, Maria Rita Gismondo, Andrea Gori, Giuliano Rizzardini, Spinello Antinori, Fausto Baldanti, Angelo Valerio Marzano, Giulia Marchetti, Francesco Castelli, Antonella Castagna, Silvia Nozza, Davide Mileto
No abstract text is available yet for this article.
April 4, 2024: Clinical Infectious Diseases
#30
JOURNAL ARTICLE
Ryan K Shields, Wendy Y Cheng, Kalé Kponee-Shovein, Daniel Indacochea, Chi Gao, Fernando Kuwer, Ashish V Joshi, Fanny S Mitrani-Gold, Patrick Schwab, Diogo Ferrinho, Malena Mahendran, Lisa Pinheiro, Jimmy Royer, Madison T Preib, Jennifer Han, Richard Colgan
BACKGROUND: In clinical practice, challenges in identifying patients with uncomplicated urinary tract infections (uUTIs) at risk of antibiotic non-susceptibility may lead to inappropriate prescribing and contribute to antibiotic resistance. We developed predictive models to quantify risk of non-susceptibility to four commonly prescribed antibiotic classes for uUTI, identify predictors of non-susceptibility to each class, and construct a corresponding risk categorization framework for non-susceptibility...
April 4, 2024: Clinical Infectious Diseases
#31
JOURNAL ARTICLE
Kaleb H Wolfe, Virginia M Pierce, Romney M Humphries
Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but current and proposed regulatory policies from the United States Food and Drug Administration (FDA) jeopardize the future availability of AST for many microorganisms. Devices that perform AST must be cleared by the FDA using their susceptibility test interpretive criteria, also known as breakpoints. The FDA list of breakpoints is relatively short. Today, laboratories supplement FDA breakpoints using breakpoints published by the Clinical and Laboratory Standards Institute, using legacy devices and laboratory-developed tests (LDTs)...
April 4, 2024: Clinical Infectious Diseases
#32
JOURNAL ARTICLE
Edward R Cachay, Tari Gilbert, Huifang Qin, Wm Christopher Mathews
BACKGROUND: Due to the heterogeneity of risk for invasive anal cancer (IAC) among people with human immunodeficiency virus (PWH), we investigated predictors of IAC and described outcomes among those with a cancer diagnosis. METHODS: Using a longitudinal inception cohort of anal cancer screening, we evaluated risk factors and outcome probabilities for incident IAC in Cox models. Screening included anal cytology and digital anorectal examination, and, if results of either were abnormal, high-resolution anoscopy...
April 4, 2024: Clinical Infectious Diseases
#33
JOURNAL ARTICLE
Genovefa A Papanicolaou, Robin K Avery, Catherine Cordonnier, Rafael F Duarte, Shariq Haider, Johan Maertens, Karl S Peggs, Carlos Solano, Jo-Anne H Young, Martha Fournier, Rose Ann Murray, Jingyang Wu, Tien Bo, Drew J Winston
No abstract text is available yet for this article.
April 4, 2024: Clinical Infectious Diseases
#34
JOURNAL ARTICLE
Jose F Camargo, Yoichiro Natori
No abstract text is available yet for this article.
April 4, 2024: Clinical Infectious Diseases
#35
JOURNAL ARTICLE
Paula Rodríguez-Molino, Marc Tebruegge, Antoni Noguera-Julian, Olaf Neth, Katy Fidler, Folke Brinkmann, Talia Sainz, Inga Ivaskeviciene, Nicole Ritz, Maria Joao Brito, Tiago Milheiro Silva, Vira Chechenieva, Maryna Serdiuk, Laura Lancella, Cristina Russo, Aleix Soler-García, Maria Luisa Navarro, Renate Krueger, Cornelia Feiterna-Sperling, Anna Starshinova, Antonina Hiteva, Anna Hoffmann, Paulius Kalibatas, Andrea Lo Vecchio, Sara Maria Scarano, Matilde Bustillo, Daniel Blázquez Gamero, María Espiau, Danilo Buonsenso, Lola Falcón, Louise Turnbull, Elena Colino, Santiago Rueda, Charlotte Buxbaum, Begoña Carazo, Cristina Alvarez, Marta Dapena, Anabel Piqueras, Svetlana Velizarova, Iveta Ozere, Florian Götzinger, Marta Pareja, Maria Isabel Garrote Llanos, Beatriz Soto, Sonia Rodríguez Martín, Jose Javier Korta, Beatriz Pérez-Gorricho, Mercedes Herranz, Ángel Hernández-Bartolomé, Mariana Díaz-Almirón, Malte Kohns Vasconcelos, Laura Ferreras-Antolín, Begoña Santiago-García
BACKGROUND: In high-resource settings the survival of immunocompromised (IC) children has increased and immunosuppressive therapies are increasingly being used. This study aimed to determine the clinical characteristics, performance of diagnostic tools and outcome of IC children with TB in Europe. METHODS: Multicentre, matched case-control study within the Paediatric Tuberculosis Network European Trials Group (ptbnet), capturing TB cases <18 years diagnosed 2000-2020...
April 3, 2024: Clinical Infectious Diseases
#36
JOURNAL ARTICLE
Anthony T Podany, Yoninah Cramer, Marjorie Imperial, Susan L Rosenkranz, Anchalee Avihingsanon, Roberto Arduino, Wadzanai Samaneka, Irina Gelmanova, Rada Savic, Susan Swindells, Rodney Dawson, Anne F Luetkemeyer
BACKGROUND: One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for TB prevention in people with HIV (PWH). However, rifapentine may decrease antiretroviral drug concentrations and increase the risk of virologic failure. ACTG A5372 evaluated the effect of 1HP on the pharmacokinetics of twice daily dolutegravir. METHODS: A5372 was a multicenter, pharmacokinetic study in PWH (≥18 years) already on dolutegravir-containing antiretroviral therapy with HIV RNA < 50 copies/mL...
April 3, 2024: Clinical Infectious Diseases
#37
JOURNAL ARTICLE
Nadine Tschumi, Blaise Lukau, Katleho Tlali, Lipontso Motaboli, Mpho Kao, Mathebe Kopo, Kathrin Hänggi, Moleboheng Mokebe, Klaudia Naegele, Irene Ayakaka, Karoline Leuzinger, Jennifer A Brown, Niklaus D Labhardt
BACKGROUND: Since 2019, the World Health Organization has recommended dolutegravir-based antiretroviral therapy (ART) as the preferred regimen for HIV management. Large-scale programmatic transitioning to dolutegravir-based ART was subsequently implemented across Africa, often in the absence of recent viral load testing and without access to genotypic resistance testing (GRT) in case of viremia. METHODS: This study assessed for emerging dolutegravir resistance in the routine care Viral Load Cohort North-East Lesotho (VICONEL)...
April 3, 2024: Clinical Infectious Diseases
#38
JOURNAL ARTICLE
Ian McGovern, Katherine Cappell, Alina N Bogdanov, Mendel D M Haag
BACKGROUND: Research on influenza burden in adults has focused on crude subgroups with cut-points at 65-years, limiting insight into how burden varies with increasing age. This study describes the incidence of influenza-related outpatient visits, emergency room (ER) visits, and hospitalizations, along with healthcare resource use and complications in the aging adult population. METHODS: Individuals ≥18 years of age in the United States were evaluated retrospectively in five seasonal cohorts (2015-2020 seasons) in strata of age with 5-year increments...
April 3, 2024: Clinical Infectious Diseases
#39
JOURNAL ARTICLE
Emily A G Faherty, Taylor Holly, Yasmin P Ogale, Hillary Spencer, Ashley M Becht, Gordon Crisler, Michael Wasz, Patrick Stonehouse, Hannah J Barbian, Christy Zelinski, Alyse Kittner, Dorothy Foulkes, Kendall W Anderson, Tiffany Evans, Lavinia Nicolae, Amber Staton, Carla Hardnett, Michael B Townsend, William C Carson, S Satheshkumar Panayampalli, Christina L Hutson, Crystal M Gigante, Laura A S Quilter, Susan Gorman, Brian Borah, Stephanie R Black, Massimo Pacilli, David Kern, Janna Kerins, Andrea M McCollum, Agam K Rao, Irina Tabidze
BACKGROUND: After months of few mpox cases, an increased number of cases were reported in Chicago during May 2023; predominantly among fully vaccinated patients. We investigated the outbreak scope, differences between vaccinated and unvaccinated patients, and hypotheses for monkeypox virus (MPXV) infection after vaccination. METHODS: We interviewed patients and reviewed medical records to assess demographic, behavioral, and clinical characteristics, mpox vaccine status, and vaccine administration routes...
April 3, 2024: Clinical Infectious Diseases
#40
JOURNAL ARTICLE
Nakwon Kwak, Emily Henkle, Hyeontaek Hwang, Doosoo Jeon, Byung Woo Jhun, Kyung-Wook Jo, Young Ae Kang, Hyung-Jun Kim, Joong-Yub Kim, Young Ran Kim, Yong-Soo Kwon, Jae Ho Lee, Jeongha Mok, Youngmok Park, Tae Sun Shim, Hojoon Sohn, Jake Whang, Jae-Joon Yim
BACKGROUND: Improving health-related quality of life (HRQOL) has emerged as a priority in the management of nontuberculous mycobacterial pulmonary disease (NTM-PD). We aimed to evaluate HRQOL and its changes after 6 months' treatment in patients with NTM-PD. METHODS: The NTM-KOREA is a nationwide prospective cohort enrolling patients initiating treatment for NTM-PD in 8 institutions across South Korea. We conducted the Quality of Life-Bronchiectasis (QOL-B) at 6-month intervals and evaluated baseline scores (higher scores indicate better quality of life) and changes after 6 months' treatment...
April 2, 2024: Clinical Infectious Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
